These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 11264037)

  • 1. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy.
    Bush K
    Clin Infect Dis; 2001 Apr; 32(7):1085-9. PubMed ID: 11264037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of beta-lactamases.
    Bush K
    Ciba Found Symp; 1997; 207():152-63; discussion 163-6. PubMed ID: 9189640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current challenges in antimicrobial chemotherapy: the impact of extended-spectrum beta-lactamases and metallo-beta-lactamases on the treatment of resistant Gram-negative pathogens.
    Helfand MS; Bonomo RA
    Curr Opin Pharmacol; 2005 Oct; 5(5):452-8. PubMed ID: 16084766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria.
    Bush K; Fisher JF
    Annu Rev Microbiol; 2011; 65():455-78. PubMed ID: 21740228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial resistance mechanisms to beta-lactam antibiotics: assessment of management strategies.
    Dudley M
    Pharmacotherapy; 1995; 15(1 Pt 2):9S-14S. PubMed ID: 7753692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of beta-lactam antibiotic resistance in gram-negative bacteria and the impact of resistance on therapy].
    Bedenić B
    Lijec Vjesn; 1999; 121(7-8):249-57. PubMed ID: 10573961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new beta-lactamases.
    Jacoby GA; Munoz-Price LS
    N Engl J Med; 2005 Jan; 352(4):380-91. PubMed ID: 15673804
    [No Abstract]   [Full Text] [Related]  

  • 12. Risks of extended-spectrum beta-lactamases.
    BMJ Group
    Drug Ther Bull; 2008 Mar; 46(3):21-4. PubMed ID: 18337463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
    Giamarellou H
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():1-16. PubMed ID: 15953019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues.
    Cornaglia G; Akova M; Amicosante G; Cantón R; Cauda R; Docquier JD; Edelstein M; Frère JM; Fuzi M; Galleni M; Giamarellou H; Gniadkowski M; Koncan R; Libisch B; Luzzaro F; Miriagou V; Navarro F; Nordmann P; Pagani L; Peixe L; Poirel L; Souli M; Tacconelli E; Vatopoulos A; Rossolini GM;
    Int J Antimicrob Agents; 2007 Apr; 29(4):380-8. PubMed ID: 17223319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Beta-lactamases of Gram negative bacteria: never-ending clockwork!].
    Philippon A; Arlet G
    Ann Biol Clin (Paris); 2006; 64(1):37-51. PubMed ID: 16420989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minor extended-spectrum beta-lactamases.
    Naas T; Poirel L; Nordmann P
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of extended-spectrum beta-lactamases by mutation.
    Gniadkowski M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():11-32. PubMed ID: 18154525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
    Kader AA; Kumar AK
    Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired metallo-beta-lactamases: an increasing clinical threat.
    Rossolini GM
    Clin Infect Dis; 2005 Dec; 41(11):1557-8. PubMed ID: 16267726
    [No Abstract]   [Full Text] [Related]  

  • 20. [Beta-lactamases in laboratory and their role in resistance Part I.: Evolution of bacterial resistance mediated by beta-lactamases].
    Bedenić B
    Lijec Vjesn; 2004; 126(11-12):314-24. PubMed ID: 16082890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.